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Abstract
Methotrexate (MTX) has been used to treat rheumatoid arthritis at low doses and leukemia at high 
doses; however, this drug can produce severe side effects. Our hypothesis is that MTX side effects 
can be attenuated by directing the drug to the target cells (i.e., leukocytes) using cIBR peptide. To 
test this hypothesis, MTX was conjugated to the N-terminus of cIBR peptide to give MTX-cIBR 
conjugate. MTX-cIBR (5.0 mg/kg) suppressed joint arthritis in adjuvant arthritis rats and 
prevented periarticular inflammation and bone resorption of the limb joints. In vitro, the toxicity 
of MTX-cIBR peptide against Molt-3 T cells was inhibited by anti-LFA-1 antibody and cIBR 
peptide in a concentration-dependent manner, suggesting that the uptake of MTX-cIBR was 
partially mediated by LFA-1. Chemical stability studies indicated that MTX-cIBR was most stable 
at pH 6.0. The MTX portion of MTX-cIBR was unstable under acidic conditions whereas the 
cIBR portion was unstable under basic conditions. In biological media, MTX-cIBR had short half-
lives in rat plasma (44 min) and homogenized rat heart tissue (38 min). This low plasma stability 
may contribute to the low in vivo efficacy of MTX-cIBR; therefore, there is a need to design a 
more stable conjugate to improve the in vivo efficacy.
Keywords
targeted delivery; ICAM-1; cIBR; MTX-cIBR; LFA-1; methotrexate; in vitro; in vivo; chemical 
stability; enzymatic stability; arthritis
INTRODUCTION
ICAM-1/LFA-1 interactions play an important role in the process of T-cell activation and 
vascular extravasation of leukocytes through vascular endothelium for recruitment to sites of 
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infection and inflammation.1,2 Inhibition of ICAM-1/LFA-1 interactions by antibodies and 
peptides has been shown to suppress autoimmune diseases as well as allograft rejections.1–3 
cIBR peptide (cyclo(1,12)PenPRGGSVLVTGC) derived from the domain-1 (D1) of 
ICAM-1 binds to the I-domain of LFA-1 and inhibits homotypic and heterotypic T-cell 
adhesion.1,4–9 Uptake of cIBR peptide by T cells occurs via receptor-mediated endocytosis;4 
thus, it is an attractive molecule for selective delivery of cytotoxic drugs to leukocytes. The 
uptake of cIBR was determined using FITC conjugate with cIBR (FITC-cIBR), and FITC-
cIBR was internalized by Molt-3 and HL-60 cells via receptor-mediated endocytosis.4,10,11 
As a negative control, FITC-cIBR was not internalized by human umbilical vein endothelial 
cells (HUVEC), which do not express lymphocyte function-associated antigen-1 (LFA-1) 
receptors.
Methotrexate (MTX) is used to treat leukemia at high doses12,13 and autoimmune diseases 
such as rheumatoid arthritis at low doses.14,15 The normal cellular uptake of MTX is 
mediated by reduced folate carriers (RFC) and membrane folate-binding proteins (mFBP); 
thus, these cellular uptake processes contribute to non-selectivity for different cells, which 
causes side effects.16 MTX may also generate drug resistance due to (a) changes in RFC 
expression level and altered transport kinetics, and (b) increased dihydrofolate reductase 
(DHFR) expression with continued use of the drug.12,17–19 Several other reasons for MTX 
resistance have also been proposed in the literature.18,20 MTX has been effectively delivered 
to cells using its conjugates with different carrier molecules, including peptides,20 
proteins,21,22 and polymers.23,24 Using target receptors other than RFC for cellular entry, the 
conjugate may possibly avoid cellular drug resistance. Normally, MTX is conjugated to the 
carrier peptides or proteins via the γ-carboxylic acid of MTX to the amino group in the 
carrier because the α-carboxylic acid group of MTX is necessary for binding to DHFR.4
In this work, MTX was conjugated to the cIBR peptide to produce MTX-cIBR (Figure 1A) 
for selective delivery of MTX to leukocytes for potential treatment of rheumatoid arthritis 
and leukemia. The hypothesis is that MTX-cIBR is directed toward LFA-1-expressing 
leukocytes over cells that do not express LFA-1, so the conjugate would have lower side 
effects than MTX alone. In vivo activity of the conjugate was determined in the rat adjuvant 
arthritic model. To study the in vitro selectivity, the activity of the conjugate to kill human 
Molt-3 T-cells was assessed in the presence and absence of cIBR peptide and anti-LFA-1 
antibodies. Chemical stability study of MTX-cIBR was conducted under accelerated 
conditions at different pH values. Finally, the enzymatic stability determination was carried 
out in plasma and liver homogenates to determine the dosing regimen during the in vivo 
study and for future optimization of the physicochemical properties of the conjugate.
EXPERIMENTAL METHODS
Materials
All reagents for peptide synthesis and stability study were purchased from Peptides 
International (Louisville, KY), Advanced ChemTech (Louisville, KY), Applied Biosystems 
(Foster City, CA), Sigma (St. Louis, MO), and Fisher Chemical (Fair Lawn, NJ). All 
solvents for peptide synthesis were of analytical grade. Amber-colored 1.0 mL ampoules 
were from Wheaton Science Products (Millville, NJ). FITC-labeled and unlabeled 
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monoclonal anti-human CD11a antibody (clone 38) was purchased from Ancell (Bayport, 
MN). MOLT-3 cells, a leukemia-derived human T-cell line, were purchased from ATCC 
(Rockville, MD). These cells were propagated in RPMI-1640 medium (Sigma, St. Louis, 
MO) containing 10% v/v fetal bovine serum and penicillin/streptomycin (100 mg/L 
medium) and incubated at 37 °C with 95% humidity and 5% CO2.
Syntheses of cIBR and MTX-cIBR
The synthesis of cIBR peptide (cyclo-1,12-PenPRGGSVLVTGC) was accomplished using 
an Fmoc solid-phase strategy. The crude product was purified using a semi-preparative 
HPLC equipped with C18 reversed-phase column. The molecular weight of cIBR peptide 
was determined by electrospray ionization mass spectrometry (M + 1 = 1174.5 amu).
The N-terminus of cIBR was conjugated to MTX-(OtBu) via its γ-carboxylic acid group on 
the Glu residue to make MTX-(OtBu)-cIBR. In this case, MTX-(OtBu) was synthesized by 
adding a solution of L-Glu(OH)-OtBu (0.132 mmol) in 5 mL of DMF dropwise into a 
mixture of 4-[N-(2,4-diamino-6-pteridinylmethyl)-N-methylamino] benzoic acid 
hemihydrochloride dihydrate (0.132 mmol), HBTU (0.132 mmol), and DIEA (0.132 mmol) 
in 5 mL of DMF. The reaction mixture was stirred under nitrogen atmosphere at room 
temperature for 2 h. The crude product was concentrated under reduced pressure to yield 
MTX-(OtBu) as yellow oil. The product was further purified by semi-preparative HPLC to 
give 87% yield. Mass spectroscopy (FAB) analysis indicated that the product had the 
expected MW of 511 (M+1).
To make MTX-cIBR, a solution of cIBR peptide (0.098 mmol) was added dropwise to a 
solution mixture of HBTU (0.098 mmol), MTX-(OtBu) (0.098 mmol), and DIEA (0.098 
mmol) in 5 mL of DMF followed by stirring under nitrogen for 3 h at room temperature. 
The reaction mixture was concentrated under reduced pressure to give an oily residue of 
MTX(OtBu)-cIBR. The resulting residue was dissolved in 3 mL of CH2Cl2 followed by 
addition of 3 mL of TFA. After the solution was stirred for 1 h at room temperature, the 
solvents were evaporated and the crude product was purified by semi-preparative HPLC 
using a C-18 column to give MTX-cIBR in 60–70% yield. The final products were analyzed 
by analytical HPLC (Figure 1B) and mass spectrometry (M + 1 = 1611, Figure 1C).
Suppression of RA in Rat Adjuvant Model by MTX-cIBR
The in vivo activity of MTX-cIBR was also determined in the rat adjuvant arthritis model 
via intravenous (i.v.) injections. Animals (7/group for adjuvant, 4/group for normal controls) 
were anesthetized with isoflurane and injected with 100 μL of Freund’s complete adjuvant 
(FCA, Sigma)/lipoidal amine (LA) at the base of the tail on day 0. MTX-cIBR (0.05, 0.2, 1, 
and 5 mg/kg) and MTX (0.05 mg/kg) were dosed i.v. once a day from day 0 to day 14. The 
animals were weighed on days 0, 4, 8, 9, 10, 11, 12, 13, and 14, at which times the dose 
volumes were adjusted accordingly. The ankle joints were measured with a caliper on day 7 
prior to the swelling onset but after establishment of systemic disease. The ankles were 
measured again on days 8, 9, 10, 11, 12, 13, and 14. Finally, the body weights were 
measured on day 14. The animals were euthanized on day 14; hind paws, liver, and spleen 
were removed and weighed. Paws and spleen were placed in formalin and then processed for 
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Hematoxylin and Eosin (H&E) staining for microscopy evaluation. All animal studies were 
approved by the Institutional Animal Care and Use Committee (IACUC). Some of the 
animal and pathology studies were done through a sub-contract with Bolder BioPath Inc., 
Boulder, CO following the approved institutional animal protocols.
MTX-cIBR Uptake by LFA-1 Receptor
The involvement of LFA-1 in the uptake of MTX-cIBR was studied by evaluating its 
toxicity in Molt-3 T-cells in the presence of increasing concentrations of cIBR peptide (10, 
100, 1000 μM) or an anti-LFA-1 antibody (clone 38) at 40 and 80 μL/mL. Molt-3 T-cells (2 
× 104 cell/mL) were incubated in a 96-well microtiter plate in the presence of either cIBR 
peptide or an anti-LFA-1 antibody (clone 38) at various concentrations. As a control, some 
cells were left untreated. The MTX-cIBR was then added to each well to a final 
concentration of 1 μM. As a reference for minimal metabolic activity, 10 mM of the 
succinate dehydrogenase inhibitor iodoacetamide (IAA) was added to untreated wells. After 
72 h of continuous exposure, the relative number of viable cells was determined using an 
MTT assay. After 4 h of incubation with a 5.0 mg/mL solution of MTT, the contents of each 
well were transferred to microcentrifuge tubes. The tubes were spun to pellet the cells, and 
the supernatant was carefully removed. The formazan crystals were dissolved in 200 μL of 
0.04 N HCl in isopropanol; the tubes were sonicated for 5 min to completely dissolve the 
crystals and then re-centrifuged to pelletize the cell debris. 100 μL aliquots of the 
supernatant solutions were removed and transferred to a 96-well microtiter plate. Then, a 
UV-Vis plate reader was used to measure the optical density at 570 nm.
Binding of MTX-cIBR to LFA-1 in response to LFA-1 activation was evaluated. Cells were 
activated with 10% v/v phorbol 12-myristate-13-acetate (PMA)-containing medium to a 
final concentration of 2 μM PMA and incubated for 16 h. 200 μL aliquots of Molt-3 T-cells 
(1 × 106 cells/mL in 1% BSA/PBS) were added to 48-well plates and treated with either 
cIBR peptide or MTX-cIBR at concentrations of 1, 10, or 100 μM for 45 min at 4 °C. The 
cells were then washed to remove unbound cIBR or MTX-cIBR. T-cells were centrifuged 
for 3 min at 1800 rpm, the supernatant was decanted by flicking off excess liquid, and the 
cells were re-suspended in 500 μL of PBS. The cells were then re-centrifuged, supernatant 
was removed, and cells were re-suspended again in 150 μL of 1% BSA/PBS. Next, 50 μL of 
an FITC-labeled anti-CD11a antibody (clone 38, 10 μg/L) was added; the cells were 
incubated for 45 min at 4 °C followed by washing. After 45-min incubation with FITC-
labeled antibody, cell samples were transferred to Eppendorf tubes and centrifuged at 3000 g 
for 3 min. The supernatant was decanted, and the pellet was washed twice with 10 mM 
HEPES/PBS. The cells were then fixed with ice-cold 2% w/v paraformaldehyde/PBS for 20 
min. The cells were analyzed using a Becton-Dickinson FACScan flow cytometer with 
3.2.1f1 software for data analysis and acquisition. Reduction in binding of the FITC-labeled 
antibody was calculated as a fraction of fluorescence remaining after incubation with cIBR 
or MTX-cIBR compared to the fluorescence of FITC-antibody binding untreated cells.
Chemical Stability Study of MTX-cIBR
The stability of MTX-cIBR was determined at 70 °C. 100 μM of MTX-cIBR was prepared 
in suitable buffer and 130 μL of conjugate solution was transferred to 1 mL amber, flame-
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sealed ampoules. Triplicate samples were removed from the oven and analyzed immediately 
at certain time points. A calibration curve was prepared for the conjugate, and the 
concentration range for the calibration curve was maintained wide enough to follow two 
half-lives for the degradation of the conjugate. For the calibration curve, each concentration 
value was determined in triplicate.
All samples were analyzed for degradation using a Hewlett Packard 1050 reversed-phase 
HPLC system with UV absorbance detection (220 nm). A Zorbax C18 column (2.1 × 50 
mm, 5 μm particle size) was used as the stationary phase, and the column temperature was 
maintained constant throughout the analysis. Samples were removed from the oven at each 
time point and transferred to an HPLC sample vial. 10 μL of the sample was injected each 
time using a gradient program that started with 100% solvent A (94.9% water, 5% 
acetonitrile and 0.1% formic acid) and was increased to 16% solvent B (94.9% acetonitrile, 
5% water and 0.1% formic acid) over 12 min followed by a ramp to increase the 
composition of solvent B to 100% by 14 min. The system was maintained at 100% B for 2 
min followed by a gradient change to 100% A over 4 min. All the concentrations were 
converted to Log concentration (Log C). Mean and standard deviation were measured for 
each time point for each pH value. Plots of Log C with time (h) were generated in SigmaPlot 
(version 9.01, Systat Software, Inc., Chicago, IL) and rate constants for degradation and 
half-lives were calculated from the plots. A plot of kobs with different pH values was used to 
create a pH rate profile for the conjugate at 70 °C. Ion-product of water (Kw) was calculated 
at 70 °C for the pH rate profile determination.
Degradation products were identified using a Q-Tof (Waters Micromass, Milford, MA) 
system equipped with electrospray ionization capability. For data collection and analysis, 
Masslynx™ (version 4.0) software was used. For the LC analysis, a Zorbax C18 column (5 
cm × 1 mm, 3.5 μm, Micro-Tech Scientific, Vista, CA) was used. Mobile phase composition 
was kept at 99% A (98.92% water, 1% acetonitrile, and 0.08% formic acid) for 1 min (flow 
rate 0.11 mL/min), reduced to 90% A over the next 1 min and to 80% A over the next 6 min 
(flow rate 0.11 mL/min). Solvent composition was changed to 95% B (98.94% acetonitrile, 
1% water, and 0.06% formic acid) over the next 7 min to flush the column (flow rate 0.15 
mL/min), and then the composition was changed back to 99% A over 2 min (flow rate 0.13 
mL/min). The injection volume for each sample was kept at 5 μL.
Stability of MTX-cIBR in Rat Plasma
The stability of MTX-cIBR was evaluated in rat plasma by preparing a stock solution of 100 
μM MTX-cIBR in DMSO. 10 μL of stock solution was mixed with 990 μL of rat plasma and 
incubated at 37 °C in a water bath (Precision reciprocal shaking bath, Model 2870, Thermo 
Electron Corporation, Waltham, MA). 100 μL samples were drawn after 0, 10, 20, 30, 45, 
60, 90, and 120 min of incubation. Samples were immediately treated with 500 μL of chilled 
acetonitrile containing internal standard alprenolol (1 μg/mL). All samples were vortexed for 
10 s and incubated on ice, followed by centrifugation at 14,000 rpm for 15 min (Eppendorf 
Refrigerated Microcentrifuge, Model 5417R). Aliquots (100 μL) of the supernatant were 
injected into the mass spectrometer. The standard curve was prepared by adding known 
concentrations of MTX-cIBR solution to rat plasma followed by immediate addition of cold 
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acetonitrile containing internal standard. Solutions for the standard curve were treated in the 
same way as the samples. Each time point was measured in triplicate, and the data are 
represented as percent concentration remaining at each time point.
Stability of MTX-cIBR in Homogenized Rat Heart
Tissue stability of MTX-cIBR was evaluated by incubating the conjugate with homogenized 
rat heart. 6.28 mL of Dulbecco’s PBS (1X) solution without Ca2+ and Mg2+ (Mediatech, 
Inc. Cellgro®, Manassas, VA) was added to 3.18 g of rat heart tissue in a test tube. The 
tissues in different tubes were homogenized using a sonifier (Branson Sonifier, Branson 
Ultrasonic Corp., Danbury, CT) for 3–5 min. From the stock solution of MTX-cIBR used in 
the plasma stability studies, 10 μL of the compound solution was mixed with 990 μL of 
tissue homogenate and incubated at 37 °C in a water bath. At different time points (0, 10, 
20, 30, 45, 60, 90, 120 min) after incubation, triplicate samples were drawn and treated in 
the same way as described above for plasma stability studies.
LC-MS Analysis of MTX-cIBR Degradation in Biological Matrices
An Integrated Cohesive Technologies LX-2 series liquid chromatography system 
(comprised of pump, autosampler, valve interface module) coupled with a 4000 Q Trap 
triple quadrupole mass spectrometer (Applied Biosystems MDS-SCIEX) was used to 
quantify the compound extracted from the biological matrices. The mass spectrometer was 
equipped with a Turbo ion-spray ionization source, and was operated in the positive mode. 
Samples were detected by multiple-reaction monitoring (MRM) scan mode. For 
chromatographic separation, an Agilent Technologies Eclipse XDB-C18 column (4.6 × 15 
mm, 3.5 μm particle diameter) was used with solvent A (10 mM ammonium formate buffer 
at pH 3.5) and solvent B (acetonitrile with 0.1% formic acid) with a flow rate of 1.0 mL/
min. A combination of linear and step gradients was used for the liquid chromatography 
separation with the following solvent composition changes: (a) 90% A to 10% A over 17 
sec, (b) 10% A maintained for 2 min, (c) changed to 90% A over 50 s, and (d) maintained at 
90% A for 17 s.
RESULTS
In Vivo Efficacy of MTX-cIBR in Arthritis Animals
The in vivo efficacies of MTX-cIBR at different doses (0.05, 0.2, 1.0, and 5.0 mg/kg) were 
determined using the rat adjuvant arthritis model generated via intravenous (i.v.) injections 
compared to vehicle-treated arthritis rats, 0.05 mg/kg MTX-treated arthritis rats, and normal 
control rats. The efficacy of MTX-cIBR in arthritis animals was monitored over 14 days by 
comparing the observed parameters such as ankle diameter, paw weight, inflammation, and 
bone resorption (Table 1). The paw weight of the arthritis animals injected with vehicle was 
approximately double that of the normal animals at day 14. There was a significant 
reduction (73% reduction) in the paw weight in rats treated with 5 mg/kg of MTX-cIBR 
compared to vehicle-treated animals (0% reduction as control). Only a small reduction in 
paw weight (7–11%) was observed on the animals treated with 0.5–1.0 mg/kg of MTX-cIBR 
(Table 1). Injection of 5.0 mg/kg MTX-cIBR significantly suppressed the increase in ankle 
diameter over 14 days compared to animals treated with vehicle (Figure 2, Table 1). For 
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lower doses (0.05, 0.2, and 1.0 mg/kg), MTX-cIBR-treated animals had a significant 
reduction (17–23%) in ankle diameter compared to that of vehicle-treated animals, 
especially on days 13 and 14 (Figure 2, Table 1). Animals treated with 5.0 mg/kg of MTX-
cIBR had a 56% reduction in joint inflammation and a 71% reduction in bone resorption 
scores compared to vehicle-treated animals (Table 1); at lower doses of MTX-cIBR, the 
differences in inflammation and bone resorption were not observed (Table 1).
The effect of MTX-cIBR was also evaluated by ankle histology compared to controls 
(Figure 3). The ankle histology of a normal rat showed normal synovium (S) and 
periarticular tissue, articular cartilage (blue arrows), epiphyseal bone (E), and distal tibia 
growth plate (black arrow) (Figure 3A). At a magnification of 100x, the distal tibia has a 
normal epiphyseal bone (E) and growth plate (black arrow) (Figure 3B). The ankle of a 
vehicle-treated rat had severe synovitis (S) and periarticular inflammation due to edema and 
neutrophil infiltration (Figures 3C and 3D). The black arrow indicates the presence of bone 
resorption across the physis with fragments of bone (green arrow) undergoing resorption in 
the medullary cavity (Figure 3D). Minor bone resorption was present in epiphyseal bone (E) 
while the articular cartilage was unaffected (blue arrow). The growth plate (Figure 3D) had 
bone loss associated with pyogranulomatous marrow inflammation and numerous 
osteoclasts. Fragmented bone trabeculae (green arrow) had undergone osteoclastic 
destruction with only minor changes in eiphyseal (E) bone.
The ankle joints of animals treated with MTX (0.05 mg/kg) had severe synovitis (S) and 
periarticular inflammation due to edema and neutrophil infiltration (Figures 3E and 3F). 
Moderate bone resorption was present across the physis (black arrow), with fragments of 
bone (green arrow) undergoing resorption in the medullary cavity (Figure 3F). Minor bone 
resorption also occurred in epiphyseal bone (E) with unaffected articular cartilage (blue 
arrows). Moderate bone loss was found associated with pyogranulomatous marrow 
inflammation and numerous osteoclasts. Some fragmented bone trabeculae (green arrow) 
were undergoing osteoclastic destruction, but maintained connectivity (Figure 3F).
The ankle of a rat treated with 5 mg/kg of MTX-cIBR had moderate synovitis (S) and 
periarticular inflammation due to edema and neutrophil infiltration (Figure 3G). No bone 
resorption was observed at the physis (black arrow), and trabeculae filled the medullary 
cavity. No bone resorption was present in epiphyseal bone (E), and the articular cartilage 
(blue arrow) was unaffected. At high magnification (100x, Figure 3H), the growth plate 
showed normal bone and growth plate cartilage.
Effects of MTX-cIBR on Body Weight and Spleen and Liver Inflammation
The effects of MTX-cIBR on the animal body, spleen, and liver weights were measured. As 
expected, the normal animals gained weight throughout the study. The arthritis animals 
treated with 5.0 mg/kg MTX-cIBR gained weight on days 0–8 and their bodyweights 
remained constant after day 8 (Figure 4). In contrast, animals treated with vehicle, MTX 
(0.05 mg/kg), and low doses of MTX-cIBR (0.05–1.0 mg/kg) lost weight after day 8.
MTX-cIBR had an effect on the spleens of treated rats. The spleen of a normal rat had large 
areas of lymphoid white pulp (W) and surrounding red pulp (R) with reticuloendothelial 
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cells; small fuci of extramedullary hematopoiesis (EMH) were not visible at this 
magnification (Figure 5A). On the other hand, the spleen of an arthritis rat treated with 
vehicle had a large area of pyogranulomatous inflammation (black outline), decreased 
lymphoid white pulp (W), and increased EMH as red pulp (R) (Figure 5B). Treatment of the 
arthritis rat with 0.05 mg/kg MTX (Figure 5C) and 0.05 mg/kg of MTX-cIBR (data not 
shown) indicated that the spleen had multi-focal small areas of pyogranulomatous 
inflammation (black tracing) and mildly decreased white pulp (W) due to lymphoid atrophy 
with moderate EMH in the red pulp (R). It was interesting to find that the spleens of rats 
treated with of MTX-cIBR at a dose of 5 mg/kg (Figure 5D) as well as 1.0 and 0.2 mg/kg 
(data not shown) had no areas of pyogranulamatous inflammation. The spleens of rats 
treated with 5 mg/kg had normal white pulp (W) and red pulp (R). The 0.2 and 1 mg/kg 
dose-treated rats had spleens with mildly decreased white pulp (W) due to lymphoid atrophy 
and moderate extramedullary hematopoiesis in the red pulp (R) (data not shown).
The differences in spleen histopathology from normal, untreated arthritis, and drug-treated 
arthritis rats were quantified using the following scoring scale: 0 = normal, 1 = minimal, 2 = 
mild, 3 = moderate, 4 = marked, 5 = severe (Figure 6). The inflammation was significantly 
decreased in a dose-dependent manner, and no inflammation was found in the spleens of rats 
treated with 1 and 5 mg/kg MTX-cIBR. Remarkably, the spleen of rats treated with 0.05 
mg/kg of MTX-cIBR had less inflammation than those treated with 0.05 mg/kg MTX 
(Figure 6). The lymphoid atrophy decreased as the dose of MTX-cIBR increased, with the 
lowest lymphoid atrophy in animals treated with 5.0 mg/kg of MTX-cIBR. Only the spleens 
from animals treated with 5.0 mg/kg of MTX-cIBR had significantly lower EMH compared 
to vehicle-treated animals, and there was no observable EMH difference in animals treated 
with 0.05 to 2.0 mg/kg MTX-cIBR and those treated with vehicle. There were increases in 
the spleen and liver weights in arthritic rats compared to normal rats (Table 2). Treatment of 
arthritic rats with 5.0 mg/kg MTX-cIBR suppressed the increases in spleen and liver weights 
by 78%. Lowering the dose of MTX-cIBR to 1.0 mg/kg lowered its ability to suppress the 
increase in spleen and liver weights by 49% and 30%, respectively.
LFA-1-Mediated Uptake of MTX-cIBR
The LFA-mediated uptake of MTX-cIBR in Molt-3 T cells was evaluated by inhibiting the 
toxicity of 1 μM MTX-cIBR in the presence of different concentrations of anti-LFA-1 mAb 
and cIBR peptide (Table 3). The viability of T cells was increased upon increasing 
concentrations of anti-LFA-1 mAb and cIBR peptide, indicating that the MTX-cIBR uptake 
was partially mediated by LFA-1. Conversely, MTX-cIBR and cIBR peptide were used to 
inhibit anti-CD11a antibody binding (clone 38, Accurate) in both PMA-activated Molt-3 T-
cells at 4 °C. MTX-cIBR and cIBR peptide inhibited binding of anti-LFA-1 mAb (clone 38) 
in PMA-activated cells in a concentration-dependent manner (data not shown).
Chemical Stability of MTX-cIBR
Degradation of MTX-cIBR was monitored at pH 1, 4, 5, 6, 7, 8, 10, and 12, and the 
degradation products at acidic and basic pH values were identified. Upon incubation at 70 
°C, the samples were analyzed up to two half-lives, and the degradation profile for MTX-
cIBR appeared to follow pseudo-first-order kinetics at all pH values. The Log C of MTX-
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cIBR was plotted against time for all pH values, and the half-lives of the conjugate are 
shown in Table 4. MTX-cIBR has the longest t1/2 at pH 6.0 (770.00 min) and the second 
longest at pH 7.0 (577.50 min).
The overall stability profile of MTX-cIBR was also expressed in the pH-rate profile (Figure 
7), which could be used to develop a suitable condition for the formulation of this conjugate. 
The highest stability was shown at pH 6.0, and two inflection points were observed at pH 
3.9 and 8.9, which were due to the protonation-deprotonation of the carboxylic acid and 
amino groups, respectively. This pH-rate profile was constructed with the following 
assumptions: (a) the ionization of the two carboxylic groups occurs at the same pH, (b) the 
tertiary amine in the MTX can be neutral or protonated, and (c) the two amino groups on the 
pteridine ring are considered to be highly unreactive and their contributions negligible. It has 
been reported previously that the amines in heterocyclic ring systems of methotrexate, 
purines, and pyrimidines are highly unreactive.20 Thus, MTX-cIBR was treated as a 
molecule with three ionizable groups (a carboxylic acid, a tertiary amine, and a guanidium 
group). Because the guanidium group has a pKa of 12.5 and the maximum pH value studied 
in this experiment was 12, the system was considered to have three species with two 
different equilibrium constants for the dissociation, as shown in the following equation with 
Ka1 and Ka2 as the equilibrium constants, respectively:
The overall degradation kinetics for the conjugate is described by the following equation:
where
The observed rate constant shown below was obtained by substituting the values for the 
fraction of the individual species.
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Because the study was conducted at 70 °C, the value of the ion product of water (pKw) was 
calculated using the empirical relationship below.
From the model, the values for the constants were:
where kH is the rate constant for acid-catalyzed degradation of H3A2+, and k′OH and k″OH 
are the rate constants for the base-catalyzed degradation of H2A+ and HA, respectively, as 
shown above. kO and k′O are the rate constants for water-catalyzed degradation of the 
H3A2+ and H2A+ species, respectively.
Degradation of MTX-cIBR under Acidic Conditions
MTX-cIBR degraded rapidly at pH 1.0 with a half-life of 1.32 h (Table 4). However, the 
stability of the compound increased dramatically at pH 4.0 (t1/2 = 216.56 h). The 
degradation products of the conjugate at acidic pH were analyzed by LC-MS. The parent 
MTX-cIBR (1, Figure 8) has two positive charges (m/z = 805.9), which are on the side chain 
of the arginine residue and the tertiary amine of MTX. Because the degradation products at 
pH 1.0 and 4.0 were similar, only the products at pH 1.0 were identified. There were two 
major degradation products of the conjugate with double charges (2, m/z = 718.8; 3, m/z = 
711.8) as determined using the isotopic distribution profiles. Compound 2 is the cleavage 
product of the C–N bond between the 6-methylpteridine and phenyl rings (pathway a, 
Figure 8), and the bond cleavage may be assisted by a positively charged tertiary amine as a 
leaving group (Figure 8). Compound 2 degraded further to compound 3 by releasing the 
methyl group from the phenyl amine moiety (pathway b, Figure 8). The HPLC profile 
indicated that the abundance of compound 3 gradually decreased with the increase in pH 
value, suggesting that the reaction was pH-dependent. To confirm the identity of compounds 
2 and 3, we showed that they both produced compound 4 with m/z = 1303.6 (z = +1) when 
they were subjected to fragmentation. This suggested that the degradation was, in fact, in the 
drug portion of the conjugate, as the cIBR peptide was intact even in this fragmentation 
product (pathway c, Figure 8).
Degradation of MTX-cIBR at Basic Conditions
Under basic conditions, as expected, the conjugate had the lowest stability at pH 12 (t1/2 = 
9.29 h, Table 4). The degradation characteristics at pH 10 were similar to those at pH 12; 
therefore, only the degradation products at pH 12 were identified. The parent MTX-cIBR 
showed a single peak before incubation at pH 12; upon incubation at pH 12, four peaks with 
the same molecular weight (i.e., 805.9, z = +2) appeared in the extracted ion 
chromatograms. These four products could be attributed to derivatives of compound 7 with 
different stereoisomers on the Ser and Thr residues of the peptide portion of the conjugate 
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(Figure 9). The stereoisomers were generated by a racemization reaction, which occurred at 
the Ser6 or Thr10 residues. The Ser and Thr residues may undergo dehydration and 
rehydration reactions to racemize the α-carbon and give a mixture of L-/D-Ser or L-/D-Thr. 
This hypothesis was supported by the observation of four different dehydrated peaks with 
m/z 797.4 (z = +2) in the chromatograms, which corresponded to compounds 5 and 6 and 
their derivatives (Figure 9). The dehydrated products 5 and 6 could only be generated via β-
elimination of the hydroxyl group in Ser6 and Thr10.
Another family of products was derived from the degradation of the disulfide bond of the 
cyclic peptide under basic conditions (Figure 10). The attack of the disulfide bond by a 
hydroxide ion led to the opening of the disulfide bond to form a sulfenic acid and a thiol 
group. One of two possible products is compound 8 (m/z = 814.9, z = +2). In this case, the 
sulfenic acid group is at the Pen1 residue of compound 8; however, the other possible 
product is the sulfenic acid group at Cys12. The thiolate group in compound 8 could react 
further with another molecule at the disulfide bond to give a dimer intermediate 9. The 
intramolecular reaction between the thiolate and sulfenic acid groups generated a cyclic 
dimer 10 with m/z 805.9 and quadruple charges (Figure 10).
In Vitro Stability of MTX-cIBR in Plasma and Tissue Homogenate
The stability of MTX-cIBR was evaluated in rat plasma and homogenized rat heart tissue to 
determine its biological disposition (Figure 11). MTX-cIBR has half-lives of 43.8 and 38.1 
min in rat plasma and homogenized rat heart, respectively.
DISCUSSION
MTX is widely used to treat the chronic inflammation of RA and Crohn’s disease; however, 
patients treated with MTX can suffer from severe side effects. To improve the efficacy 
profile of MTX, it has been conjugated to different carriers to increase its cellular uptake 
with or without targeting a specific type of cell.17,25 Because autoimmune diseases are 
characterized by ‘self-reactive’ T-cells, it would be ideal to target T cells that are responsible 
for mediating the inflammatory response. For this purpose, an integrin called LFA-1 
receptor is an ideal and selective receptor for delivering MTX to activated T cells because 
LFA-1 is expressed exclusively on leukocytes. Selective delivery of MTX to activated 
inflammatory leukocytes could provide a significant reduction in the side effects of MTX 
treatment. As a proof-of-concept, MTX-cIBR was developed and evaluated in in vitro and in 
vivo assays to demonstrate that cIBR peptide could improve delivery of MTX to leukocytes.
As previously shown using FITC-cIBR, the uptake mechanism of cIBR peptide in Molt-3 T 
cells and HL-60 cells is via receptor-mediated endocytosis through receptor clustering.4,10,11 
However, it is more difficult to evaluate the mechanism of endocytosis of MTX-cIBR 
compared to that of FITC-cIBR using fluorescence microscopy; this is due to the low 
fluorescence emission of MTX. Thus, several alternative methods were carried out to 
indirectly evaluate receptor-mediated endocytosis of MTX-cIBR. First, binding of MTX-
cIBR to LFA-1 receptors on T cells was inhibited by anti-LFA-1 mAb, suggesting that cIBR 
fragment on the conjugate binds to LFA-1 receptors. MTX-cIBR was more effective in 
inhibiting anti-LFA-1 mAb in PMA-activated T cells than in resting T cells, suggesting that 
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MTX-cIBR preferably binds to the activated form of LFA-1 receptors. It could also suggest 
that binding of MTX-cIBR to LFA-1 induces the internalization of LFA-1 receptors on the 
activated T cells. Second, the toxicity of the MTX-cIBR in Molt-3 T cells was also inhibited 
by cIBR peptide or an anti-LFA-1 monoclonal antibody in a concentration-dependent 
manner (Table 3). This result indicated that MTX-cIBR entered the cells partially using 
LFA-1 receptors to elicit MTX toxicity. It should be noted that MTX-cIBR could enter the 
cells via RFC and mFBP receptors upon recognition of the MTX fragment. The mechanism 
of entry of MTX-cIBR via LFA-1 vs. (RFC + mFBP) has not been fully elucidated at this 
time. Thirdly, although the cytotoxicity of MTX-cIBR (IC50 = 2.75 μM) was 45-fold lower 
than MTX (IC50 = 0.061 μM) against LFA-1-expressing Molt-3 T cells, MTX-IBR was not 
toxic up to 10 μM against non-LFA-1-expressing KB epithelial cells.26 In contrast, MTX 
has a similar range of toxicity (IC50 = 0.027 μM) in KB epithelial cells and in Molt-3 T cells 
(IC50 = 0.061 μM). These results suggest that the LFA-1-mediated endocytosis differentiates 
the selectivity of MTX-cIBR over MTX in T cells and KB epithelial cells. The lower cell 
toxicity of MTX-cIBR could be due to the structural interference of cIBR fragment on the 
binding of MTX fragment to DHFR. This steric interference reduced the DHFR inhibitory 
activity of MTX-cIBR (Km = 29.8±2.1 × 10−9 M) by 15-fold compared to MTX (Km = 
1.8±0.7 × 10−9 M).26 Taken together, the results suggest that the uptake of MTX-cIBR is via 
receptor-mediated endocytosis and that DHFR inhibitory activity may not necessarily be due 
to the release of MTX from MTX-cIBR.
The in vivo efficacy of MTX-cIBR was evaluated in the rat adjuvant arthritis model; it 
should be noted that cIBR peptide has a similar amino acid sequence in human, mouse, or 
rat ICAM-1. The efficacy was determined by evaluating the joint inflammation and the 
inhibition of periarticular inflammation and bone resorption of developing adjuvant arthritis. 
The secondary endpoints of this conjugate efficacy include the inhibition of splenomegaly, 
hepatomegaly, and body weight change of adjuvant disease. Treatment of arthritic rats with 
5.0 mg/kg of MTX-cIBR was effective in suppressing the progress of arthritis with an 
increase in animal body weight over time. The animals had moderate synovium and no bone 
resorption at the physis. In contrast, the adjuvant rats treated with vehicle had severe 
synovitis and periarticular inflammation due to edema and neutrophil infiltration. In 
addition, these animals had bone resorption across the physis with the presence of bone 
fragments. Due to the toxicity of MTX, the activity of MTX-cIBR could not be compared to 
that of MTX at a high dose (i.e., 5.0 mg/kg). Although animals treated daily with 0.2 mg/kg 
had excellent suppression of RA, the animals did not show an increase in body weight, 
possibly due to the toxicity of MTX at a high dose.
Unfortunately, MTX-cIBR was not as effective at a 1-mg/kg dose. One possible explanation 
is that the conjugate is not very stable in the systemic circulation. Clearly, this molecule was 
rapidly eliminated in the blood upon i.v. injections in the animal model of RA as indicated 
by low plasma stability (t1/2 = 43.8 min). This may explain the need to deliver a higher dose 
(5 mg/kg) of the conjugate before observing significant efficacy compared to vehicle. 
However, the low dose (0.2–1.0 mg/kg) significantly suppressed the spleen inflammation 
(Figure 6). Even at a 0.05-mg/kg dose, MTX-cIBR suppressed spleen inflammation better 
than 0.05 mg/kg of MTX alone (Figure 6, Table 2). The rapid peptide metabolism of MTX-
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cIBR could be attributed to the presence of the Arg residue that makes the peptide prone to 
trypsin digestion. The disulfide bond in the cyclic peptide could be opened by reaction with 
glutathione in plasma and tissue. In addition, the MTX portion of the molecule could be 
metabolized to form 2,4-diamino-7-hydroxy-pteridine.27 Although the disulfide bond is 
unstable, several peptide drugs such oxytocin28 and integrilin29 are currently being used for 
inducing labor and for treating myocardial infarction, respectively. These cyclic peptides 
have been successfully developed with sufficient in vivo stability to produce in vivo 
biological activity. In the case of MTX-cIBR, the rationales to select cIBR for conjugation 
were (a) its mechanism of uptake of cIBR has been well studied,4,10,11 (b) the N-terminal of 
cIBR is available for conjugation to MTX, and (c) cIBR peptide has also been shown to 
suppress RA in the collagen-induced arthritis (CIA) mouse model.30
Conjugation of MTX to cIBR maintains the binding properties of cIBR peptide to LFA-1 
because MTX-cIBR can inhibit binding of anti-LFA-1 mAb to LFA-1 on Molt-3 T-cells. 
These results suggest that conjugation of MTX to cIBR does not alter the binding 
characteristics of the cIBR-peptide fragment to LFA-1. MTX-cIBR preferably binds to the 
activated state of LFA-1 on activated Molt-3 T cells. LFA-1 recognition of the cIBR-peptide 
fragment within the MTX-conjugate may be due to the preservation of the peptide 
conformation after conjugation. The NMR structure of the conjugate showed that the β-turn 
conformation of the important PRG sequence in the cIBR peptide of MTX-cIBR was not 
altered by conjugation to MTX (data not shown). This PRG motif in cIBR peptide is 
essential for binding LFA-1 and inhibiting T-cell adhesion.6 However, the NMR structure 
showed that the turn around the Val-Thr-Gly sequence on the MTX-cIBR was altered upon 
conjugation by moving it to the opposite side compared to the cIBR peptide (data not 
shown). Because the conjugate demonstrated binding characteristics to LFA-1 similar to 
those of cIBR, this suggests that the conformational difference in the Val-Thr-Gly sequence 
may not influence the binding properties of MTX-cIBR.
It is also important to determine the chemical stability of the conjugate for future 
development of its formulation. Furthermore, degradation mechanisms of the conjugate can 
be utilized to design a more stable molecule. Interestingly, the MTX portion of the conjugate 
is more prone to degradation in acidic conditions than in basic conditions. There are two 
degradation pathways of the MTX segment of the conjugate. The first is the release of the 
pteridine ring from the conjugate (pathway a, Figure 8) to give compound 2. This release is 
due to the cleavage of the C-N bond between the pteridine ring and the p-amino-benzoyl 
ring. This reaction is assisted by the presence of the protonated tertiary amine of the p-
amino-benzoyl group, which acts as a good leaving group. The second major degradation 
product was produced by demethylation of the phenylamine moiety (pathway b, Figure 8) 
of compound 2 to give compound 3.
The major degradation sites for the peptide portion of the conjugate are at the Ser6 and 
Thr10 residues and at the disulfide bond. The Ser6 and Thr10 residues degrade via β-
elimination under both acidic and basic conditions. Under basic conditions, the dehydration 
reaction is also observed as the major degradation pathway of the peptide segment. After 
incubation in basic conditions, four peaks with the same molecular weight as the parent 
conjugate were observed. These compounds are due to racemization at the α-carbon of Ser6 
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and Thr10 to give four possible conjugates with (1) L-Ser6 and L-Thr10 (the parent 
compound), (2) L-Ser6 and D-Thr10, (3) D-Ser and L-Thr10, and (4) D-Ser6 and D-Thr10. 
Racemization of the Ser residue in peptides has been observed previously in RS-26306 
decapeptide and the LHRH analog histrelin.31,32 The mechanism of racemization is 
supported by the presence of four different dehydration products (e.g., compounds 5 and 6) 
of the conjugate. It was not possible to identify each of these peaks individually due to the 
lack of separation and their co-elution with the dimer products. Our attempts to improve the 
separation of these molecules were unsuccessful. In addition, the fragmentation of the 
dehydrated species failed to yield additional information because the 6-methylpteridine-2,4-
diamine ring carried most of the ion current that led to the suppression of the signal from the 
peptide fragments.
Finally, the disulfide bond can be cleaved directly by hydroxide ion to produce thiolate-
sulfenic acid 8; this type of reaction has been observed previously in cyclic peptides.33,34 
The thiolate anion can attack a disulfide bond in another molecule of conjugate to produce a 
linear dimer 9. The intramolecular reaction of the thiolate ion on the sulfur of sulfenic acid 
generates the cyclic dimer 10 and releases hydroxyl anion.
The fact that MTX-cIBR is most stable at pH 6.0 is advantageous for formulation 
development of the conjugate as it is close to physiological pH (pH 7.4). Peptides and 
proteins with higher stability in highly acidic or alkaline pH often present a challenge in 
formulation development. Indications that MTX-cIBR is unstable in the presence of 
biological matrices combined with the identification of the chemical degradation 
mechanisms will help to design a more stable conjugate. Identification of the in vivo 
degradation products as well as the pharmacokinetic profile will be evaluated in the future.
One way to improve the in vivo efficacy of MTX-cIBR is by stabilizing the cIBR peptide via 
elimination of the disulfide bond. In this case, the peptide can be cyclized via N-to-C-
terminus peptide bond. To achieve this goal, an initial effort has been made to design a 
cyclic hexapeptide (CH7, cyclo(1,6)PRGGSV); this peptide has activity comparable to that 
of cIBR in inhibiting ICAM-1/LFA-1-mediated heterotypic T-cell adhesion upon binding to 
LFA-1.6 Because CH7 does not have a free amino group for conjugation to MTX, CHK7 
peptide (cyclo(1,6)PRGGKV) peptide was synthesized by replacing Ser-5 with Lys-5 to 
provide the side chain amino group. Unfortunately, CHK7 has lower cell adhesion inhibitory 
activity than the parent CH7, indicating lower LFA-1 binding affinity. Therefore, further 
Lys mutation studies are being carried out to find a good position for the lysine residue in 
CHK7 that does not lower binding affinity of CHK7 to LFA-1. Once a CHK7 derivative 
with similar LFA-1 binding affinity with cIBR peptide is found, MTX can be conjugated to 
CHK7 derivative to make MTX-CHK7 for in vitro and in vivo evaluations. Another way to 
improve the efficacy of the MTX-peptide conjugate is by increasing the separation between 
MTX and the peptide. Molecular modeling studies indicated that cIBR peptide could 
interfere with MTX binding to DHFR; this is one possible reason that MTX-cIBR has lower 
DHFR inhibitory activity than MTX. In this case, different lengths of spacer or linker 
between the peptide and MTX can be introduced to reduce peptide interference during 
binding of MTX fragment to DHFR. Alternatively, the MTX can be conjugated to the 
peptide via a cleavable linker that is sensitive to enzymatic cleavage (i.e., esterase) or pH 
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change in lysosomes to release MTX in the intracellular space. Finally, a full comparison of 
dose-dependent efficacy and toxicity of MTX-cIBR, MTX, and cIBR can be carried out to 
determine the potential advantages of the conjugate.
In conclusion, cIBR has a potential to deliver MTX to leukocytes for suppressing 
rheumatoid arthritis in the animal model. The cIBR peptide improves the delivery of MTX 
to LFA-1-expressing leukocytes, and the in vitro results suggest that the conjugate binds to 
LFA-1 on T cells. However, the contributions of RFC and mFBP to the uptake of MTX-
cIBR compared to those of LFA-1 should be evaluated in the future. The conjugate also had 
short half-lives in plasma and tissue homogenates, which could explain why the conjugate 
was not effective in vivo at low doses. Therefore, there is an effort our laboratory to design a 
conjugate that is more stable than MTX-cIBR in biological systems. Finally, the mechanism 
of action of MTX-cIBR in suppressing inflammatory T cells (i.e., Th1 and Th17) and 
possibly enhancing suppressor/regulatory T cells (i.e., Th2 and Treg) will be investigated.
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Structure and characterization of MTX-cIBR: (A) chemical structure of MTX-cIBR, (B) 
analytical reversed-phase HPLC chromatogram of pure MTX-cIBR, and (C) mass 
spectrometry spectrum of pure MTX-cIBR.
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The efficacy of MTX-cIBR at different concentrations (0.05–5.0 mg/kg) in suppressing the 
increase in ankle diameters of arthritis rats compared to arthritis rats treated with vehicle, 
0.05 mg/kg MTX, and normal rats. The results were from measuring two paws per rat with n 
= 7 for arthritis rats and n = 4 for normal rats. * = p-value < 0.05 when compared to vehicle-
treated arthritis rats.
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Histology photomicrographs of the left ankle joints at low (16x) and high (100x) 
magnifications. The photomicrographs of a representative ankle joint of a normal rat at (A) 
16x and (B) 100x; a diseased rat treated with vehicle at (C) 16x and (D) 100x; a disease rat 
treated with 0.05 mg/kg MTX at (E) 16x and (F) 100x; a diseased rat treated with 5 mg/kg 
MTX-cIBR at (G) 16x and (H) 100x. Synovium (S); articular cartilage (blue arrows); 
fragment of bone (green arrow); epiphyseal bone (E); and distal tibial growth plate (black 
arrow).
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The effect of increasing doses of MTX-cIBR (0.05–5.0 mg/kg) on the increase in animal 
bodyweight compared to controls (i.e., vehicle and 0.05 mg/kg MTX). The animals treated 
with 5.0 mg/kg MTX-cIBR maintained their bodyweight significantly compared to vehicle-
treated animals. n = 7 for arthritis rats and n = 4 for normal rats. * = p-value < 0.05 when 
compared to vehicle-treated arthritis rats.
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Photomicrograph of spleen dissection from (A) normal rat treated with vehicle, (B) arthritis 
rat treated with vehicle, (C) arthritis rat treated with 0.05 mg/kg of MTX, and (D) arthritis 
rat treated with MTX-cIBR (5 mg/kg). W = lymphoid white pulp. R = red pulp with 
reticuloendothelial cells.
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The scores of inflammation, lymphoid atrophy, and extramedullary hemotopoiesis (EMH) of 
normal and arthritis rat treated with vehicle, MTX (0.05 mg/kg), and MTX-cIBR (0.05. 0.2, 
1, and 5 mg/kg). * indicates the statistical significance with p value ≤ 0.05.
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pH-rate profile for MTX-cIBR at 70 °C with buffer concentrations and ionic strength as 
described in Table 4. Stability of the conjugate was followed at pH values 1, 4, 5, 6, 7, 8, 10, 
and 12. Maximum stability of the conjugate was observed at pH 6.
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Identification of the major degradation products of MTX-cIBR at pH 1.0. Pathway a shows 
the degradation of the MTX portion of the conjugate by clipping the C-N bond between the 
pteridine ring and the p-amino-benzoyl ring to give compound 2. Pathway b represents 
demethylation reaction of compound 2 to give degradation product 3. Pathway c shows 
cleavage between the p-amino-benzoyl group and the Glu residue of the MTX fragment of 
the conjugate (compound 4).
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Identification of the major degradation products for MTX-cIBR at pH 12. The conjugate can 
undergo dehydration and racemization at the Ser6 and Thr10 residues. Compounds 5 and 6 
are representative of the dehydration reaction of the Thr10 and Ser6 residues. Subsequent 
attack by hydroxyl ions on the alkene groups produces Ser6 and Thr10 with mixed chirality 
(L- and D-amino acid) in compound 7.
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The disulfide bond degradation in MTX-cIBR at pH 12 produced thiolate-sulfenic acid 8 
and cyclic dimer 10. The disulfide bond opening was via direct attack of hydroxyl anion on 
the sulfur of the disulfide bond. Thiolate 8 was reacted with another molecule of the 
conjugate to produce a linear dimer 9; intramolecular reaction of thiolate anion with the 
sulfur atom of sulfenic acid generated a cyclic dimer 10.
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Determination of the stability of the MTX-cIBR in isolated rat plasma and homogenized rat 
heart tissue. Stability of the conjugate was determined over a period of 2 half-lives. Pseudo-
first-order plots were generated from the degradation profiles.
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Table 1
The effect of MTX-cIBR on suppressing arthritis in the limbs of rats using different parameters at Day 14.
Treatment Paw Weight ± SE 
(g)
AUC Paw Ankle 
Diameter ± SE
Inflammation Score ± SE Bone Resorption Score 
± SE
Normal + Vehicle 1.7761 ± 0.0262 
(100%) *
1.927 ± 0.005 (100%) * 0.00 ± 0.0 (100%) * 0.0 ± 0.0 (100%) *
Arthritis + Vehicle 3.5825 ± 0.0866 
(0%)
2.420 ± 0.028 (0%) 5.0 ± 0.0 (0%) 3.9 ± 0.4 (0%)
Arthritis + 0.05 mg/kg MTX-
cIBR
3.3780 ± 0.1104 
(11%)
2.305 ± 0.036 (23%) ** 4.6 ± 0.2 (9%) ** 4.0 ± 0.4 (−1%)
Arthritis + 0.2 mg/kg MTX-
cIBR
3.4321 ± 0.1212 
(8%)
2.336 ± 0.035 (17%) 4.7 ± 0.2 (6%) 4.5 ± 0.2 (−15%)
Arthritis + 1 mg/kg MTX-cIBR 3.4582 ± 0.0850 
(7%)
2.309 ± 0.030 (22%)** 4.9 ± 0.1 (1%) 3.6 ± 0.4 (8%)
Arthritis + 5 mg/kg MTX-cIBR 2.2680± 0.2227 
(73%) *
2.050 ± 0.049 (75%) ** 2.2 ± 0.5 (56%) * 1.1 ± 0.5 (71%) *
Arthritis + 0.05 mg/kg MTX 3.5790 ± 0.0877 
(0%)
2.388 ± 0.028 (6%) 4.9 ± 0.1 (3%) 3.1 ± 0.4 (22%)
*
p-value < 0.01 when compared to Arthritis + Vehicle.
**
p-value < 0.05 when compared to Arthritis + Vehicle.
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Table 2
The effect of MTX-cIBR on spleen and liver weights at Day 14.
Treatment Rat Spleen Weight ± SE (g) Rat Liver Weight ± SE (g)
Normal + Vehicle 0.2139 ± 0.0060 (100%) * 4.3689 ± 0.1475 (100%) *
Arthritis + Vehicle 0.5823 ± 0.0175 (0%) 6.6191 ± 0.0858 (0%)
Arthritis + 0.05 mg/kg MTX-cIBR 0.4524 ± 0.0139 (35%) * 5.8817 ± 0.0690 (33%) *
Arthritis + 0.2 mg/kg MTX-cIBR 0.4822 ± 0.0248 (27%) 6.1970 ± 0.1721 (19%) **
Arthritis + 1 mg/kg MTX-cIBR 0.4027 ± 0.0202 (49%) * 5.9485 ± 0.1947 (30%) *
Arthritis + 5 mg/kg MTX-cIBR 0.2953 ± 0.017 (78%) * 4.8620 ± 0.2053 (78%) *
Arthritis + 0.05 mg/kg MTX 0.500 ± 0.000 (11%) 6.1289 ± 0.1451 (22%) **
*
p-value < 0.01 when compared to Arthritis + Vehicle.
**
p-value < 0.05 when compared to Arthritis + Vehicle.
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Table 3
Protective Effect of cIBR Peptide or CD11a mAb against MTX-cIBR Activity (1 μM).
cIBR peptide [μM] % Viable cells CD11a antibody dose % Viable cells
10 58 ± 3 40 μL/mL 35 ± 7
100 81 ± 7 80 μL/mL 97 ± 10
1000 94 ± 5
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Table 4
The observed pseudo-first-order rate constants and half-lives for MTX-cIBR at different pH conditions at 70 
°C.
pH Buffer type kobs(h−1) t1/2(h)
1.0 HCl 5.25 × 10−1 1.32
4.0 Acetate 3.2 × 10−3 216.56
5.0 Acetate 1.3 × 10−3 533.08
6.0 Phosphate 9 × 10−4 770.00
7.0 Phosphate 1.2 × 10−3 577.50
8.0 Phosphate 3.1 × 10−3 223.55
10.0 Carbonate 2.3 × 10−2 30.13
12.0 NaOH 7.4 × 10−2 9.29
Ionic strengths of all buffer solutions were adjusted to 0.15 M with NaCl. For pH 1.0, a solution of 0.1 N HCl was used; 0.01 N NaOH was used for 
pH 12. For all other pH values, buffer concentration was kept at 50 mM.
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